Merck Soars as Analysts Upgrade Stock to Buy Amid Ongoing Success of Keytruda and Future Growth Potential

Merck & Co., Inc. (MRK), the pharmaceutical giant behind the blockbuster cancer treatment Keytruda, saw its stock price surge following an upgrade from Deutsche Bank analysts. The bank upgraded MRK from a hold to a buy, citing “clear path” for growth beyond the patent cliff of Keytruda in 2027. The upgrade reflects confidence in Merck’s diversified pipeline and expanding product portfolio. Beyond Keytruda, the company is working on several promising treatments, including its cancer therapies pensio and niraparib, as well as its infectious disease medications, such as molnupiravir. Deutsche Bank analysts highlighted MRK’s strong financial position, with a solid balance sheet and significant cash reserves, which will enable the company to fund future research and development initiatives. The bank also expects MRK’s growth prospects to be driven by the increasing demand for cancer treatments, particularly in Asia. Keytruda has been instrumental in Merck’s success, generating billions of dollars in revenue since its approval in 2014. However, the patent cliff poses a significant challenge to the company’s long-term growth prospects. Deutsche Bank analysts argue that MRK’s diversified pipeline and emerging markets opportunities provide a “clear path” beyond the Keytruda patent cliff. The stock has gained over 20% year-to-date, driven by investor optimism about the company’s future prospects. Analysts at Jefferies also upgraded MRK to a buy earlier this month, citing its growth potential in emerging markets and expanding cancer therapy portfolio. With several upgrades from major banks, Merck shares are poised for further gains as investors become increasingly optimistic about the company’s long-term prospects.